IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-18077-5.html
   My bibliography  Save this article

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Author

Listed:
  • Liqiang Feng

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    First Affiliated Hospital of Guangzhou Medical University)

  • Qian Wang

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    University of Chinese Academy of Sciences)

  • Chao Shan

    (State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences)

  • Chenchen Yang

    (Guangzhou nBiomed Ltd)

  • Ying Feng

    (First Affiliated Hospital of Guangzhou Medical University)

  • Jia Wu

    (State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences)

  • Xiaolin Liu

    (Guangzhou nBiomed Ltd)

  • Yiwu Zhou

    (Tongji Medical College of Huazhong University of Science and Technology)

  • Rendi Jiang

    (State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences)

  • Peiyu Hu

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Xinglong Liu

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Fan Zhang

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Pingchao Li

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Xuefeng Niu

    (First Affiliated Hospital of Guangzhou Medical University)

  • Yichu Liu

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Xuehua Zheng

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Jia Luo

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Jing Sun

    (First Affiliated Hospital of Guangzhou Medical University)

  • Yingying Gu

    (First Affiliated Hospital of Guangzhou Medical University)

  • Bo Liu

    (Guangzhou nBiomed Ltd)

  • Yongcun Xu

    (Guangzhou nBiomed Ltd)

  • Chufang Li

    (First Affiliated Hospital of Guangzhou Medical University)

  • Weiqi Pan

    (First Affiliated Hospital of Guangzhou Medical University)

  • Jincun Zhao

    (First Affiliated Hospital of Guangzhou Medical University)

  • Changwen Ke

    (Guangdong Provincial Center for Disease Control and Prevention)

  • Xinwen Chen

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Tao Xu

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences)

  • Nanshan Zhong

    (First Affiliated Hospital of Guangzhou Medical University)

  • Suhua Guan

    (Guangzhou nBiomed Ltd)

  • Zhiming Yuan

    (State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences)

  • Ling Chen

    (Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
    First Affiliated Hospital of Guangzhou Medical University
    Guangzhou nBiomed Ltd)

Abstract

The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.

Suggested Citation

  • Liqiang Feng & Qian Wang & Chao Shan & Chenchen Yang & Ying Feng & Jia Wu & Xiaolin Liu & Yiwu Zhou & Rendi Jiang & Peiyu Hu & Xinglong Liu & Fan Zhang & Pingchao Li & Xuefeng Niu & Yichu Liu & Xuehua, 2020. "An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques," Nature Communications, Nature, vol. 11(1), pages 1-11, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18077-5
    DOI: 10.1038/s41467-020-18077-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-18077-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-18077-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Haisheng Yu & Banghui Liu & Yudi Zhang & Xijie Gao & Qian Wang & Haitao Xiang & Xiaofang Peng & Caixia Xie & Yaping Wang & Peiyu Hu & Jingrong Shi & Quan Shi & Pingqian Zheng & Chengqian Feng & Guofan, 2023. "Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants," Nature Communications, Nature, vol. 14(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18077-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.